Kazia Therapeutics Ltd (KZIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Kazia (KZIA)

Kazia Therapeutics (KZIA) is attracting top oncologists and scientists due to its clinical trial successes, which strengthens its R&D potential. The stock's price history demonstrates an EV/EBITDA multiple of 0.00, illustrating the valuation of a business developing molecules to cross the blood-brain barrier for aggressive brain tumors. Its monopoly status in a niche segment and FDA patent protection preclude price wars with competitors.

KZIA Kazia Therapeutics Limited: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/15/2026

KZIA (Kazia Therapeutics Ltd): analytical breakdowns and indicator data

- stock price and consensus target price:
Summary company analytics:KZIA (Kazia)
Original product of Kazia Therapeutics Limited

This ratio relates the total enterprise value, including debt, to operating profit before taxes, depreciation, and amortization, allowing for an assessment of the real value of assets without the influence of credit load. For Kazia Therapeutics (KZIA) and its narrow specialization in brain cancer therapy, this metric is critical as it reflects the resilience of capitalization against the risks of failed clinical trials. Analyzing the EV/EBITDA chart helps investors timely recognize asset overvaluation amid the high volatility of the biopharmaceutical sector.

Competitor analysis

Incyte Corporation - Enterprise Value to EBITDA Ratio|hutch-med.com (HCM) - Company Value to EBITDA|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Day One Biopharmaceuticals, Inc.|Monopar Therapeutics (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (i-mabbiopharma.com) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio fennecpharma.com (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences, Inc CHRS|Corbus Pharmaceuticals, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc.|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Lixte Biotechnology Holdings LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA Cellectar Biosciences CLRB|Enterprise Value to EBITDA Ratio BLRX (BioLineRx Ltd.)|CANF (Can-Fite BioPharma Ltd.) - Business Value to Operating Income Before Depreciation|Aprea Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion)|NuCana - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix, Inc)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Pharma (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Corp (PRTG)